NASDAQ:VTGN VistaGen Therapeutics Q1 2027 Earnings Report $0.24 +0.00 (+0.49%) As of 02:36 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast VistaGen Therapeutics EPS ResultsActual EPS-$0.30Consensus EPS -$0.37Beat/MissBeat by +$0.07One Year Ago EPSN/AVistaGen Therapeutics Revenue ResultsActual Revenue$1.48 millionExpected Revenue$0.50 millionBeat/MissBeat by +$976.00 thousandYoY Revenue GrowthN/AVistaGen Therapeutics Announcement DetailsQuarterQ1 2027Date8/14/2026TimeBefore Market OpensConference Call DateFriday, August 14, 2026Conference Call Time8:30AM ETUpcoming EarningsVistaGen Therapeutics' Q2 2027 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) VistaGen Therapeutics Earnings HeadlinesVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Rating of "Reduce" from AnalystsAugust 29, 2026 | americanbankingnews.comVistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate UpdateAugust 14, 2026 | globenewswire.comGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet production stayed at 5.9 million ounces, unchanged from 2020. Newmont, Barrick and Agnico all face the same reserve shortage, pushing majors toward acquiring smaller producing miners. Recent deals show the pattern: Rupert Resources jumped 67 percent and G2 Goldfields jumped 79 percent the day their buyouts were announced. Analyst Garrett Goggin has identified four junior miners he believes are next on the shopping list.September 8 at 1:00 AM | Golden Portfolio (Ad)Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety DisorderAugust 6, 2026 | globenewswire.comSRX Global (NYSE American: SRXH) Acquires Stake in Vistagen TherapeuticsAugust 4, 2026 | markets.businessinsider.comVistagen Appoints Douglas J. Williamson to its Board of DirectorsJuly 31, 2026 | globenewswire.comSee More VistaGen Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like VistaGen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VistaGen Therapeutics and other key companies, straight to your email. Email Address About VistaGen TherapeuticsVistaGen Therapeutics (NASDAQ:VTGN) (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions. The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain. VistaGen also develops PH-10, a topical neuroactive small molecule in clinical development for psoriasis and atopic dermatitis. To broaden its development reach, VistaGen has entered strategic partnerships, including a licensing agreement with Yuhan Corporation for AV-101 in South Korea, and continues to advance its clinical and regulatory strategy primarily in North America and Asia. VistaGen’s proprietary Human Clinical Drug Rescue and ReRationalization platform employs patient-derived pluripotent stem cell–derived neural and cardiac cells to predict clinical efficacy and safety, reduce late-stage development risk and complement traditional preclinical models. This platform supports both in-house pipeline programs and collaborative research initiatives. Leading the company is President and Chief Executive Officer Shawn K. Singh, who has overseen VistaGen’s research and corporate development efforts since joining in 2014 and remains committed to translating innovative science into new therapeutic options for underserved patient populations.View VistaGen Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 AI Optical Networking Stocks Positioned for the Data Center BuildoutSafety Stocks Are Not What They Used to Be: 4 Names Built for a Weaker DollarMarketBeat Week in Review – 08/31 - 09/04Why Guidewire’s Post-Earnings Plunge May Not LastPalo Alto vs. Zscaler: Which Cybersecurity Stock Looks Stronger After Earnings?Short Sellers Are Betting Against 3 AI Infrastructure Stocks—What Could Turn the Tide?Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
